中国药品专利商品化研究

Research on Commercialization of Chinese Pharmaceutical Patents

专利商品化是提升制药企业竞争力最有效的外部途径。通过对2007—2016年中国授权药品专利的商品化数据分析发现,非企业是NME和NCE专利的主要研发主体、企业是药品增量创新专利的研发主体、国外专利权人在华专利更具有商品化价值、国内专利权人的药品专利授权数量多但商品化数量少、国内非企业和企业的研发分工不明确。建议政府从主观和客观两方面对国内研发主体的研发分工进行细分引导,进一步完善当前专利资助模式,从弱化专利的非商品属性等方面入手,解决当前中国药品专利商品化所面临的问题。

Patent commercialization is the most effective external way to enhance the competitiveness of pharmaceutical companies. By analyzing the commercial data of Chinese granted pharmaceutical patents from 2007 to 2016, it finds that non-enterprise entities are the main R＆D bodies of NME and NCE patents. The enterprises are the main R＆D bodies of drug incremental innovative patents. The patents owned by the foreign entities have higher commercial value, but more authorized pharmaceutical patents held by the domestic patentee have less commercializafion. The division of R＆D is unreasonable between domestic non-enterprises entities and enterprises. In order to solve the problems faced by Chinese pharmaceutical R＆D bodies in the progress of patents commercialization, the author puts for- ward some recommendations. The government should guide different domestic R＆D entities to carry out specialized division of labor through subjective and objective aspects, further improve the pattern of the patent subsidy and weaken the non-commodity attribute of patent.